Department Medical Imaging, University Medical Imaging Toronto, University Health Network - Mount Sinai Hospital - Women College Hospital, University of Toronto, Toronto, Ontario, Canada.
Department of Diagnostic Imaging, Chaim Sheba Medical Center, Ramat Gan, Israel.
Nucl Med Commun. 2024 Dec 1;45(12):1039-1046. doi: 10.1097/MNM.0000000000001895. Epub 2024 Oct 15.
The purposes was to build model incorporating PET + computed tomography (CT) radiomics features from baseline PET/CT + clinical parameters to predict outcomes in patients with non-Hodgkin lymphomas.
Cohort of 138 patients with complete clinical parameters and follow up times of 25.3 months recorded. Textural analysis of PET and manual correlating contouring in CT images analyzed using LIFE X software. Defined outcomes were overall survival (OS), disease free-survival, radiotherapy, and unfavorable response (defined as disease progression) assessed by end of therapy PET/CT or contrast CT. Univariable and multivariable analysis performed to assess association between PET, CT, and clinical.
Male ( P = 0.030), abnormal lymphocytes ( P = 0.030), lower value of PET entropy ( P = 0.030), higher value of SHAPE sphericity ( P = 0.002) were significantly associated with worse OS. Advanced stage (III or IV, P = 0.013), abnormal lymphocytes ( P = 0.032), higher value of CT gray-level run length matrix (GLRLM) LRLGE mean ( P = 0.010), higher value of PET gray-level co-occurrence matrix energy angular second moment ( P < 0.001), and neighborhood gray-level different matrix (NGLDM) busyness mean ( P < 0.001) were significant predictors of shorter DFS. Abnormal lymphocyte ( P = 0.033), lower value of CT NGLDM coarseness ( P = 0.082), and higher value of PET GLRLM gray-level nonuniformity zone mean ( P = 0.040) were significant predictors of unfavorable response to chemotherapy. Area under the curve for the three models (clinical alone, clinical + PET parameters, and clinical + PET + CT parameters) were 0.626, 0.716, and 0.759, respectively.
旨在构建包含基线 PET/CT 放射组学特征和临床参数的模型，以预测非霍奇金淋巴瘤患者的预后。
本研究纳入了 138 例患者，记录了完整的临床参数和 25.3 个月的随访时间。使用 LIFE X 软件对 PET 和手动 CT 图像轮廓相关的纹理分析。根据治疗结束时的 PET/CT 或对比 CT，定义总生存（OS）、无疾病生存、放疗和不良反应（定义为疾病进展）为结局。采用单变量和多变量分析评估 PET、CT 和临床参数之间的相关性。
男性（ P = 0.030）、异常淋巴细胞（ P = 0.030）、较低的 PET 熵值（ P = 0.030）、较高的 SHAPE 球形度（ P = 0.002）与 OS 较差显著相关。晚期（III 或 IV 期， P = 0.013）、异常淋巴细胞（ P = 0.032）、较高的 CT 灰度游程长度矩阵（GLRLM）LRLGE 均值（ P = 0.010）、较高的 PET 灰度共生矩阵能量角二阶矩（ P < 0.001）和邻域灰度差矩阵（NGLDM）忙度均值（ P < 0.001）是 DFS 较短的显著预测因子。异常淋巴细胞（ P = 0.033）、较低的 CT NGLDM 粗糙度（ P = 0.082）和较高的 PET GLRLM 灰度不均匀性区域均值（ P = 0.040）是化疗不良反应的显著预测因子。三个模型（仅临床、临床+PET 参数和临床+PET+CT 参数）的曲线下面积分别为 0.626、0.716 和 0.759。
